Quadramet

Quadramet is a radiopharmaceutical that is used in the treatment of pain caused by bone metastases. It is a type of radiation therapy that is administered intravenously. The active ingredient in Quadramet is samarium-153 (153Sm), a radioisotope that emits beta particles.

Mechanism of action

Quadramet works by binding to areas in the bone where there is increased osteoblastic activity, such as where bone metastases are present. The beta particles emitted by the samarium-153 cause localized damage to the cancer cells, helping to relieve pain.

Uses

Quadramet is used to treat pain caused by bone metastases in patients with cancer. It is often used when the pain has not responded to more conservative treatments, such as analgesics or opioids. It can also be used in combination with other treatments, such as chemotherapy or hormone therapy.

Side effects

The most common side effects of Quadramet are nausea, vomiting, and low blood counts. Less common side effects include fever, chills, and fatigue. Because Quadramet is a radioactive substance, there is also a risk of radiation exposure to others, especially in the first few days after treatment.

Contraindications

Quadramet is contraindicated in patients with known hypersensitivity to samarium-153 or any other component of the product. It should also be used with caution in patients with poor bone marrow reserve, as it can cause myelosuppression.

See also

• Radiopharmaceutical
• Bone metastases
• Radiation therapy
• Samarium-153

Quadramet Resources
Latest articles Most recent articles Ongoing trials	Wikipedia